HIGHLIGHTS
- who: Thomas Zilli from the Department of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, SwitzerlandDepartment of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland have published the paper: Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus, in the Journal: (JOURNAL) of 10/Oct/2022
SUMMARY
In the second round, consensus (88%) was obtained to recommend MDT for patients with de novo oligometastatic, oligorecurrent, and oligoprogressive prostate cancer, while 12% of the experts recommended MDT only for de novo oligometastatic and oligorecurrent patients (after the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.